Dr. Kathleen Moore, M.D., MS

About Kathleen Moore, M.D., MS

Education:

• Earned an MD from the University of Oklahoma College of Medicine in 1995.
• Obtained an MS in Clinical Research from the University of Oklahoma Health Sciences Center in 2007.

Experience:

• Director of the Gynecologic Oncology Fellowship Program at Stephenson Cancer Center, University of Oklahoma Health Sciences Center.
• Professor in the Department of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center.
• Renowned gynecologic oncologist and clinical researcher, specializing in ovarian cancer and other gynecologic malignancies.

Area of expertise

Affiliated Hospitals

University Of Oklahoma Health Sciences Center

University Of Oklahoma

Clinical Trials Kathleen Moore, M.D., MS is currently running

SHetA2

for Gynecologic Cancers

The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.

Recruiting1 award Phase 1

Behavioral Weight Loss + Progestin

for Endometrial Hyperplasia

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.

Recruiting1 award Phase 2

More about Kathleen Moore, M.D., MS

Other Doctors you might be interested in

Frequently asked questions